{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:57:09Z","timestamp":1767182229527,"version":"3.45.0"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05359-6","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T08:03:04Z","timestamp":1763539384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synuclein Proteoforms: Role in Health and Disease"],"prefix":"10.1007","volume":"63","author":[{"given":"Fatima Tu","family":"Zahra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooreen","family":"Kayani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samra","family":"Noreen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8692-3161","authenticated-orcid":false,"given":"Aneeqa","family":"Noor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saima","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"5359_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-022-01382-z","author":"TE Moors","year":"2022","unstructured":"Moors TE, Mona D, Luehe S et al (2022) Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies. Acta Neuropathol Commun. https:\/\/doi.org\/10.1186\/s40478-022-01382-z","journal-title":"Acta Neuropathol Commun"},{"key":"5359_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G et al (2023) Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14:211. https:\/\/doi.org\/10.1038\/s41419-023-05672-9","journal-title":"Cell Death Dis"},{"key":"5359_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11092330","volume":"11","author":"N Ninkina","year":"2023","unstructured":"Ninkina N, Kukharsky MS (2023) Editorial of the special issue: recent advances in understanding of the role of synuclein family members in health and disease. Biomedicines 11:2330. https:\/\/doi.org\/10.3390\/biomedicines11092330","journal-title":"Biomedicines"},{"key":"5359_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.818606","volume":"14","author":"ML Pons","year":"2022","unstructured":"Pons ML, Loftus N, Vialaret J et al (2022) Proteomics challenges for the assessment of synuclein proteoforms as clinical biomarkers in Parkinson\u2019s disease. Front Aging Neurosci 14:818606. https:\/\/doi.org\/10.3389\/fnagi.2022.818606","journal-title":"Front Aging Neurosci"},{"key":"5359_CR5","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.10536.1","volume":"6","author":"VN Uversky","year":"2017","unstructured":"Uversky VN (2017) Looking at the recent advances in understanding \u03b1-synuclein and its aggregation through the proteoform prism. F1000Res 6:525. https:\/\/doi.org\/10.12688\/f1000research.10536.1","journal-title":"F1000Res"},{"key":"5359_CR6","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/ncomms3575","volume":"4","author":"L Bousset","year":"2013","unstructured":"Bousset L, Pieri L, Ruiz-Arlandis G et al (2013) Structural and functional characterization of two alpha-synuclein. Nat Commun 4:2575","journal-title":"Nat Commun"},{"key":"5359_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.00","volume":"79","author":"JT Bendor","year":"2013","unstructured":"Bendor JT, Logan TP, Edwards RH (2013) The function of \u03b1-synuclein. Neuron 79:1044\u20131066. https:\/\/doi.org\/10.1016\/j.neuron.2013.09.00","journal-title":"Neuron"},{"key":"5359_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00401-017-1755-1","volume":"134","author":"N Bengoa-Vergniory","year":"2017","unstructured":"Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J (2017) Alpha-synuclein oligomers: a new hope. Acta Neuropathol 134:819\u2013838. https:\/\/doi.org\/10.1007\/s00401-017-1755-1","journal-title":"Acta Neuropathol"},{"key":"5359_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3233\/JPD-171103","volume":"7","author":"C Galvagnion","year":"2017","unstructured":"Galvagnion C (2017) The role of lipids interacting with \u03b1-synuclein in the pathogenesis of Parkinson\u2019s disease. J Parkinsons Dis 7:433\u2013450. https:\/\/doi.org\/10.3233\/JPD-171103","journal-title":"J Parkinsons Dis"},{"key":"5359_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/JPD-150642","volume":"5","author":"J Burr\u00e9","year":"2015","unstructured":"Burr\u00e9 J (2015) The synaptic function of \u03b1-synuclein. J Parkinsons Dis 5:699\u2013713. https:\/\/doi.org\/10.3233\/JPD-150642","journal-title":"J Parkinsons Dis"},{"key":"5359_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13449","author":"T Tyson","year":"2016","unstructured":"Tyson T, Steiner JA, Brundin P (2016) Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. J Neurochem. https:\/\/doi.org\/10.1111\/jnc.13449","journal-title":"J Neurochem"},{"issue":"5321","key":"5359_CR12","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H et al (1997) Mutation in the \u03b1-synuclein gene identified in families with PD. Science 276(5321):2045\u20132047. https:\/\/doi.org\/10.1126\/science.276.5321.2045","journal-title":"Science"},{"key":"5359_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.neuroscience.2011.10.042","volume":"200","author":"G Muntan\u00e9","year":"2012","unstructured":"Muntan\u00e9 G, Ferrer I, Martinez-Vicente M (2012) \u0391-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 200:106\u2013119. https:\/\/doi.org\/10.1016\/j.neuroscience.2011.10.042","journal-title":"Neuroscience"},{"key":"5359_CR14","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.bbapap.2019.03.001","volume":"1867","author":"S Mehra","year":"2019","unstructured":"Mehra S, Sahay S, Maji SK (2019) \u03b1-Synuclein misfolding and aggregation: implications in Parkinson\u2019s disease pathogenesis. Biochim Biophys Acta Proteins Proteom 1867:890\u2013908. https:\/\/doi.org\/10.1016\/j.bbapap.2019.03.001","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"5359_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijms.2008.12.007","volume":"283","author":"C Chanthamontri","year":"2009","unstructured":"Chanthamontri C, Liu J, McLuckey SA (2009) Charge state dependent fragmentation of gaseous \u03b1-synuclein cations via ion trap and beam-type collisional activation. Int J Mass Spectrom 283:9\u201316. https:\/\/doi.org\/10.1016\/j.ijms.2008.12.007","journal-title":"Int J Mass Spectrom"},{"issue":"2","key":"5359_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/genes9020063","volume":"9","author":"A G\u00e1mez-Valero","year":"2018","unstructured":"G\u00e1mez-Valero A, Beyer K (2018) Alternative splicing of alpha- and beta-synuclein genes plays differential roles in synucleinopathies. Genes 9(2):63. https:\/\/doi.org\/10.3390\/genes9020063","journal-title":"Genes"},{"key":"5359_CR17","doi-asserted-by":"publisher","unstructured":"Payton JE, Perrin RJ, Clayton DF, George JM (2001) Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. Brain Res 95(1\u20132):138\u2013145. https:\/\/doi.org\/10.1016\/s0169-328x(01)00257-1","DOI":"10.1016\/s0169-328x(01)00257-1"},{"key":"5359_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1021\/acschemneuro.6b00430","volume":"9","author":"S Kumar","year":"2018","unstructured":"Kumar S, Jangir DK, Kumar R et al (2018) Role of sporadic Parkinson disease associated mutations A18T and A29S in enhanced \u03b1-synuclein fibrillation and cytotoxicity. ACS Chem Neurosci 9:230\u2013240. https:\/\/doi.org\/10.1021\/acschemneuro.6b00430","journal-title":"ACS Chem Neurosci"},{"key":"5359_CR19","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1021\/acschemneuro.7b00149","volume":"8","author":"P Ranjan","year":"2017","unstructured":"Ranjan P, Kumar A (2017) Perturbation in long-range contacts modulates the kinetics of amyloid formation in \u03b1-synuclein familial mutants. ACS Chem Neurosci 8:2235\u20132246. https:\/\/doi.org\/10.1021\/acschemneuro.7b00149","journal-title":"ACS Chem Neurosci"},{"key":"5359_CR20","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1093\/hmg\/ddu165","volume":"23","author":"MB Fares","year":"2014","unstructured":"Fares MB, Ait-Bouziad N, Dikiy I et al (2014) The novel Parkinson\u2019s disease linked mutation G51D attenuates in vitro aggregation and membrane binding of \u03b1-synuclein, and enhances its secretion and nuclear localization in cells. Hum Mol Genet 23:4491\u20134509. https:\/\/doi.org\/10.1093\/hmg\/ddu165","journal-title":"Hum Mol Genet"},{"key":"5359_CR21","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1021\/acschemneuro.1c00028","volume":"12","author":"S He","year":"2021","unstructured":"He S, Wang F, Yung KKL et al (2021) Effects of \u03b1-synuclein-associated post-translational modifications in Parkinson\u2019s disease. ACS Chem Neurosci 12:1061\u20131071. https:\/\/doi.org\/10.1021\/acschemneuro.1c00028","journal-title":"ACS Chem Neurosci"},{"key":"5359_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3389\/fnins.2019.00381","volume":"13","author":"J Zhang","year":"2019","unstructured":"Zhang J, Li X, Li J (2019) The roles of post-translational modifications on \u03b1-synuclein in the pathogenesis of Parkinson\u2019s diseases. Front Neurosci 13:381. https:\/\/doi.org\/10.3389\/fnins.2019.00381","journal-title":"Front Neurosci"},{"key":"5359_CR23","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/pro.3412","volume":"27","author":"F El Turk","year":"2018","unstructured":"El Turk F, De Genst E, Guilliams T et al (2018) Exploring the role of post-translational modifications in regulating \u03b1-synuclein interactions by studying the effects of phosphorylation on nanobody binding. Protein Sci 27:1262\u20131274. https:\/\/doi.org\/10.1002\/pro.3412","journal-title":"Protein Sci"},{"key":"5359_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1197853","volume":"16","author":"V Brembati","year":"2023","unstructured":"Brembati V, Faustini G, Longhena F, Bellucci A (2023) Alpha synuclein post translational modifications: potential targets for Parkinson\u2019s disease therapy?. Front Mol Neurosci 16:1197853. https:\/\/doi.org\/10.3389\/fnmol.2023.1197853","journal-title":"Front Mol Neurosci"},{"key":"5359_CR25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3389\/fncel.2014.00240","volume":"8","author":"A Sierra","year":"2014","unstructured":"Sierra A, Tremblay M\u00c8, Wake H (2014) Never-resting microglia: physiological roles in the healthy brain and pathological implications. Front Cell Neurosci 8:240. https:\/\/doi.org\/10.3389\/fncel.2014.00240","journal-title":"Front Cell Neurosci"},{"key":"5359_CR26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jmb.2007.07.009","volume":"372","author":"CW Bertoncini","year":"2007","unstructured":"Bertoncini CW, Rasia RM, Lamberto GR et al (2007) Structural characterization of the intrinsically unfolded protein \u03b2-synuclein, a natural negative regulator of \u03b1-synuclein aggregation. J Mol Biol 372:708\u2013722. https:\/\/doi.org\/10.1016\/j.jmb.2007.07.009","journal-title":"J Mol Biol"},{"key":"5359_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10048-011-0311-8","volume":"13","author":"K Beyer","year":"2012","unstructured":"Beyer K, Munoz-Marmol AM, Sanz C et al (2012) New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases. Neurogenetics 13:61\u201372. https:\/\/doi.org\/10.1007\/s10048-011-0311-8","journal-title":"Neurogenetics"},{"issue":"1","key":"5359_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010142","volume":"12","author":"J Hayashi","year":"2022","unstructured":"Hayashi J, Carver JA (2022) \u03b2-Synuclein: an enigmatic protein with diverse functionality. Biomolecules 12(1):142. https:\/\/doi.org\/10.3390\/biom12010142","journal-title":"Biomolecules"},{"key":"5359_CR29","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1074\/jbc.M109.081950","volume":"285","author":"MK Mbefo","year":"2010","unstructured":"Mbefo MK, Paleologou KE, Boucharaba A et al (2010) Phosphorylation of synucleins by members of the polo-like kinase family. J Biol Chem 285:2807\u20132822. https:\/\/doi.org\/10.1074\/jbc.M109.081950","journal-title":"J Biol Chem"},{"key":"5359_CR30","doi-asserted-by":"publisher","unstructured":"George JM (2001) The synucleins characteristic structural features. Genome Biol 3:(1):reviews3002.1. Available: http:\/\/genomebiology.com\/2001\/3\/1\/reviews\/3002. https:\/\/doi.org\/10.1186\/gb-2001-3-1-reviews3002","DOI":"10.1186\/gb-2001-3-1-reviews3002"},{"issue":"11","key":"5359_CR31","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1039\/c5mb00272a","volume":"11","author":"M Panneerselvam","year":"2015","unstructured":"Panneerselvam M, Muthu K, Ramadas K (2015) Structural insights into tumor-specific chaperoning activity of gamma synuclein in protecting estrogen receptor alpha 36 and its role in tamoxifen resistance in breast cancer. Mol Biosyst 11(11):2998\u20133010. https:\/\/doi.org\/10.1039\/c5mb00272a","journal-title":"Mol Biosyst"},{"key":"5359_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041067","author":"U Golebiewska","year":"2012","unstructured":"Golebiewska U, Guo Y, Khalikaprasad N et al (2012) \u03b3-Synuclein interacts with phospholipase C\u03b22 to modulate G protein activation. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0041067","journal-title":"PLoS ONE"},{"key":"5359_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/jnc.14810","volume":"150","author":"D Sulzer","year":"2019","unstructured":"Sulzer D, Edwards RH (2019) The physiological role of \u03b1-synuclein and its relationship to Parkinson\u2019s disease. J Neurochem 150:475\u2013486. https:\/\/doi.org\/10.1111\/jnc.14810","journal-title":"J Neurochem"},{"key":"5359_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086983","author":"VC Ducas","year":"2014","unstructured":"Ducas VC, Rhoades E (2014) Investigation of intramolecular dynamics and conformations of \u03b1-, \u03b2- and \u03b3-synuclein. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0086983","journal-title":"PLoS ONE"},{"key":"5359_CR35","doi-asserted-by":"publisher","unstructured":"Chris A, Ferreon M, Gambin Y et al (2009) Interplay of-synuclein binding and conformational switching probed by single-molecule fluorescence. Proc Natl Acad Sci 06(14):5645\u20135650. https:\/\/doi.org\/10.1073\/pnas.0809232106","DOI":"10.1073\/pnas.0809232106"},{"key":"5359_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nbd.2004.06.006","volume":"17","author":"GG Kov\u00e1cs","year":"2004","unstructured":"Kov\u00e1cs GG, L\u00e1szl\u00f3 L, Kov\u00e1cs J et al (2004) Natively unfolded tubulin polymerization promoting protein TPPP\/p25 is a common marker of alpha-synucleinopathies. Neurobiol Dis 17:155\u2013162. https:\/\/doi.org\/10.1016\/j.nbd.2004.06.006","journal-title":"Neurobiol Dis"},{"key":"5359_CR37","doi-asserted-by":"publisher","unstructured":"Ortigosa-Pascual L, Ferrante-Carrante N, Bernfur K et al (2025) On the transient interactions of \u03b1-synuclein in different dimensions.https:\/\/doi.org\/10.1101\/2025.01.29.635265","DOI":"10.1101\/2025.01.29.635265"},{"key":"5359_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep15164","author":"MK Janowska","year":"2015","unstructured":"Janowska MK, Wu KP, Baum J (2015) Unveiling transient protein-protein interactions that modulate inhibition of alpha-synuclein aggregation by beta-synuclein, a pre-synaptic protein that co-localizes with alpha-synuclein. Sci Rep. https:\/\/doi.org\/10.1038\/srep15164","journal-title":"Sci Rep"},{"key":"5359_CR39","doi-asserted-by":"publisher","first-page":"8748","DOI":"10.1038\/s41467-024-53086-8","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, Yu L, Liu X et al (2024) \u0392-synuclein regulates the phase transitions and amyloid conversion of \u03b1-synuclein. Nat Commun 15:8748. https:\/\/doi.org\/10.1038\/s41467-024-53086-8","journal-title":"Nat Commun"},{"key":"5359_CR40","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1471-4159.2008.05776.x","volume":"108","author":"E Israeli","year":"2009","unstructured":"Israeli E, Sharon R (2009) \u0392-synuclein occurs in vivo in lipid-associated oligomers and forms hetero-oligomers with \u03b1-synuclein. J Neurochem 108:465\u2013474. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05776.x","journal-title":"J Neurochem"},{"key":"5359_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.01399","volume":"13","author":"LD Bernal-Conde","year":"2020","unstructured":"Bernal-Conde LD, Ramos-Acevedo R, Reyes-Hern\u00e1ndez MA et al (2020) Alpha-synuclein physiology and pathology: a perspective on cellular structures and organelles. Front Neurosci 13:1399. https:\/\/doi.org\/10.3389\/fnins.2019.01399","journal-title":"Front Neurosci"},{"key":"5359_CR42","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1021\/bi300478w","volume":"51","author":"I Surgucheva","year":"2012","unstructured":"Surgucheva I, Sharov VS, Surguchov A (2012) \u03b3-Synuclein: seeding of \u03b1-synuclein aggregation and transmission between cells. Biochemistry 51:4743\u20134754. https:\/\/doi.org\/10.1021\/bi300478w","journal-title":"Biochemistry"},{"key":"5359_CR43","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.19.390419","author":"KE Carnazza","year":"2020","unstructured":"Carnazza KE, Komer L, Pineda A et al (2020) Beta- and gamma-synucleins modulate synaptic vesicle-binding of alpha-synuclein. bioRxiv. https:\/\/doi.org\/10.1101\/2020.11.19.390419","journal-title":"bioRxiv"},{"issue":"2","key":"5359_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020375","volume":"10","author":"IC Br\u00e1s","year":"2021","unstructured":"Br\u00e1s IC, Outeiro TF (2021) Alpha-synuclein: mechanisms of release and pathology progression in synucleinopathies. Cells 10(2):375. https:\/\/doi.org\/10.3390\/cells10020375","journal-title":"Cells"},{"key":"5359_CR45","doi-asserted-by":"publisher","unstructured":"Stefanis L (2012) \u03b1-Synuclein in Parkinson\u2019s disease. Cold Spring Harb Perspect Med 2. https:\/\/doi.org\/10.1101\/cshperspect.a009399","DOI":"10.1101\/cshperspect.a009399"},{"key":"5359_CR46","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1021\/acschemneuro.0c00811","volume":"12","author":"G Fani","year":"2021","unstructured":"Fani G, Mannini B, Vecchi G et al (2021) A\u03b2 oligomers dysregulate calcium homeostasis by mechanosensitive activation of AMPA and NMDA receptors. ACS Chem Neurosci 12:766\u2013781. https:\/\/doi.org\/10.1021\/acschemneuro.0c00811","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"5359_CR47","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/mds.28941","volume":"37","author":"L Barba","year":"2022","unstructured":"Barba L, PaoliniPaoletti F, Bellomo G et al (2022) Alpha and beta synucleins: from pathophysiology to clinical application as biomarkers. Movement Disord 37(4):645\u2013655. https:\/\/doi.org\/10.1002\/mds.28941","journal-title":"Movement Disord"},{"issue":"8","key":"5359_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15082051","volume":"15","author":"N Siwecka","year":"2023","unstructured":"Siwecka N, Saramowicz K, Galita G et al (2023) Inhibition of protein aggregation and endoplasmic reticulum stress as a targeted therapy for \u03b1-synucleinopathy. Pharmaceutics 15(8):2051. https:\/\/doi.org\/10.3390\/pharmaceutics15082051","journal-title":"Pharmaceutics"},{"issue":"3","key":"5359_CR49","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/jnc.13570","volume":"137","author":"MJ Benskey","year":"2016","unstructured":"Benskey MJ, Perez RG, Manfredsson FP (2016) The contribution of alpha synuclein to neuronal survival and function - implications for Parkinson\u2019s disease. J Neurochem 137(3):331\u2013359. https:\/\/doi.org\/10.1111\/jnc.13570","journal-title":"J Neurochem"},{"key":"5359_CR50","doi-asserted-by":"publisher","first-page":"690293","DOI":"10.3389\/fnagi.2021.690293","volume":"13","author":"NdeO Manzanza","year":"2021","unstructured":"Manzanza NdeO, Sedlackova L, Kalaria RN (2021) Alpha-synuclein post-translational modifications: implications for pathogenesis of Lewy body disorders. Front Aging Neurosci 13:690293. https:\/\/doi.org\/10.3389\/fnagi.2021.690293","journal-title":"Front Aging Neurosci"},{"key":"5359_CR51","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1074\/jbc.M115.705095","volume":"291","author":"F Samuel","year":"2016","unstructured":"Samuel F, Flavin WP, Iqbal S et al (2016) Effects of serine 129 phosphorylation on \u03b1-synuclein aggregation, membrane association, and internalization. J Biol Chem 291:4374\u20134385. https:\/\/doi.org\/10.1074\/jbc.M115.705095","journal-title":"J Biol Chem"},{"key":"5359_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.661117","author":"R Bell","year":"2021","unstructured":"Bell R, Vendruscolo M (2021) Modulation of the interactions between \u03b1-synuclein and lipid membranes by post-translational modifications. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2021.661117","journal-title":"Front Neurol"},{"key":"5359_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/biom12030467","author":"RE Lacoursiere","year":"2022","unstructured":"Lacoursiere RE, Hadi D, Shaw GS (2022) Acetylation, phosphorylation, ubiquitination (Oh My!): following post-translational modifications on the ubiquitin road. Biomolecules. https:\/\/doi.org\/10.3390\/biom12030467","journal-title":"Biomolecules"},{"key":"5359_CR54","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1007\/s12035-022-02897-1","volume":"59","author":"S Sahoo","year":"2022","unstructured":"Sahoo S, Padhy AA, Kumari V, Mishra P (2022) Role of ubiquitin-proteasome and autophagy-lysosome pathways in \u03b1-synuclein aggregate clearance. Mol Neurobiol 59:5379\u20135407. https:\/\/doi.org\/10.1007\/s12035-022-02897-1","journal-title":"Mol Neurobiol"},{"issue":"4","key":"5359_CR55","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4103\/1735-1995.181989","volume":"41","author":"FN Emamzadeh","year":"2016","unstructured":"Emamzadeh FN (2016) Alpha-synuclein structure, functions, and interactions. Iran J Med Sci 41(4):229\u2013236. https:\/\/doi.org\/10.4103\/1735-1995.181989","journal-title":"Iran J Med Sci"},{"key":"5359_CR56","doi-asserted-by":"publisher","first-page":"292","DOI":"10.5607\/en.2014.23.4.292","volume":"23","author":"D Snead","year":"2014","unstructured":"Snead D, Eliezer D (2014) Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol 23:292\u2013313. https:\/\/doi.org\/10.5607\/en.2014.23.4.292","journal-title":"Exp Neurobiol"},{"key":"5359_CR57","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1007\/s12035-023-03211-3","volume":"60","author":"K Moore","year":"2023","unstructured":"Moore K, Sengupta U, Puangmalai N et al (2023) Polymorphic alpha-synuclein oligomers: characterization and differential detection with novel corresponding antibodies. Mol Neurobiol 60:2691\u20132705. https:\/\/doi.org\/10.1007\/s12035-023-03211-3","journal-title":"Mol Neurobiol"},{"key":"5359_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/srep27125","author":"G Fusco","year":"2016","unstructured":"Fusco G, De Simone A, Arosio P et al (2016) Structural ensembles of membrane-bound \u03b1-synuclein reveal the molecular determinants of synaptic vesicle affinity. Sci Rep. https:\/\/doi.org\/10.1038\/srep27125","journal-title":"Sci Rep"},{"key":"5359_CR59","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.yexcr.2010.10.013","volume":"317","author":"H Zhang","year":"2011","unstructured":"Zhang H, Kouadio A, Cartledge D, Godwin AK (2011) Role of gamma-synuclein in microtubule regulation. Exp Cell Res 317:1330\u20131339. https:\/\/doi.org\/10.1016\/j.yexcr.2010.10.013","journal-title":"Exp Cell Res"},{"key":"5359_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090737","author":"C Wilding","year":"2014","unstructured":"Wilding C, Bell K, Beck S et al (2014) \u03b3-synuclein antibodies have neuroprotective potential on neuroretinal cells via proteins of the mitochondrial apoptosis pathway. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0090737","journal-title":"PLoS ONE"},{"key":"5359_CR61","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.bbrc.2016.08.052","volume":"478","author":"SC Park","year":"2016","unstructured":"Park SC, Moon JC, Shin SY et al (2016) Functional characterization of alpha-synuclein protein with antimicrobial activity. Biochem Biophys Res Commun 478:924\u2013928. https:\/\/doi.org\/10.1016\/j.bbrc.2016.08.052","journal-title":"Biochem Biophys Res Commun"},{"key":"5359_CR62","doi-asserted-by":"publisher","first-page":"578047","DOI":"10.1016\/j.jneuroim.2023.578047","volume":"l379","author":"DL Heiden","year":"2023","unstructured":"Heiden DL, Monogue B, Ali MDH, Beckham JD (2023) A functional role for alpha-synuclein in neuroimmune responses. J Neuroimmunol l379:578047. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578047","journal-title":"J Neuroimmunol"},{"key":"5359_CR63","doi-asserted-by":"publisher","unstructured":"Pavlenko TA, Roman AY, Lytkina OA et al (2023) Gamma-synuclein dysfunction causes autoantibody formation in glaucoma patients and dysregulation of intraocular pressure in mice. Biomedicines 11. https:\/\/doi.org\/10.3390\/biomedicines11010060","DOI":"10.3390\/biomedicines11010060"},{"key":"5359_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.633727","volume":"15","author":"C Liu","year":"2021","unstructured":"Liu C, Zhao Y, Xi H et al (2021) The membrane interaction of alpha-synuclein. Front Cell Neurosci 15:633727. https:\/\/doi.org\/10.3389\/fncel.2021.633727","journal-title":"Front Cell Neurosci"},{"key":"5359_CR65","doi-asserted-by":"publisher","first-page":"E4274","DOI":"10.1073\/pnas.1416598111","volume":"111","author":"J Burr\u00e9","year":"2014","unstructured":"Burr\u00e9 J, Sharma M, S\u00fcdhof TC (2014) \u0391-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci U S A 111:E4274\u2013E4283. https:\/\/doi.org\/10.1073\/pnas.1416598111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"5359_CR66","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.4103\/1673-5374.235013","volume":"13","author":"F Miraglia","year":"2018","unstructured":"Miraglia F, Ricci A, Rota L, Colla E (2018) Subcellular localization of alpha-synuclein aggregates and their interaction with membranes. Neural Regen Res 13(10):1694\u20131699. https:\/\/doi.org\/10.4103\/1673-5374.235013","journal-title":"Neural Regen Res"},{"key":"5359_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115830","author":"TN Dunn","year":"2015","unstructured":"Dunn TN, Akiyama T, Lee HW et al (2015) Evaluation of the synuclein-\u03b3 (sncg) gene as a PPAR\u03b3 target in murine adipocytes, dorsal root ganglia somatosensory neurons, and human adipose tissue. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0115830","journal-title":"PLoS ONE"},{"key":"5359_CR68","doi-asserted-by":"publisher","first-page":"20943","DOI":"10.1073\/pnas.1210022110","volume":"109","author":"S Millership","year":"2012","unstructured":"Millership S, Ninkina N, Guschina IA et al (2012) Increased lipolysis and altered lipid homeostasis protect \u03b3-synuclein-null mutant mice from diet-induced obesity. Proc Natl Acad Sci USA 109:20943\u201320948. https:\/\/doi.org\/10.1073\/pnas.1210022110","journal-title":"Proc Natl Acad Sci USA"},{"key":"5359_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00356","volume":"11","author":"M G\u00f3mez-Benito","year":"2020","unstructured":"G\u00f3mez-Benito M, Granado N, Garc\u00eda-Sanz P et al (2020) Modeling Parkinson\u2019s disease with the alpha-synuclein protein. Front Pharmacol 11:356. https:\/\/doi.org\/10.3389\/fphar.2020.00356","journal-title":"Front Pharmacol"},{"key":"5359_CR70","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1073\/pnas.1100976108","volume":"108","author":"B Winner","year":"2011","unstructured":"Winner B, Jappelli R, Maji SK et al (2011) In vivo demonstration that \u03b1-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108:4194\u20134199. https:\/\/doi.org\/10.1073\/pnas.1100976108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"5359_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/cells11111732","volume":"11","author":"M Vidovi\u0107","year":"2022","unstructured":"Vidovi\u0107 M, Rikalovic MG (2022) Alpha-synuclein aggregation pathway in Parkinson\u2019s disease: current status and novel therapeutic approaches. Cells 11(11):1732. https:\/\/doi.org\/10.3390\/cells11111732","journal-title":"Cells"},{"key":"5359_CR72","doi-asserted-by":"publisher","unstructured":"Cascella R, Bigi A, Cremades N, Cecchi C (2022) Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies. Cell Mol Life Sci 79. https:\/\/doi.org\/10.1007\/s00018-021-04060-8","DOI":"10.1007\/s00018-021-04060-8"},{"key":"5359_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2024.1498459","volume":"17","author":"HH Ho","year":"2024","unstructured":"Ho HH, Wing SS (2024) \u03b1-Synuclein ubiquitination \u2013 functions in proteostasis and development of Lewy bodies. Front Mol Neurosci 17:1498459. https:\/\/doi.org\/10.3389\/fnmol.2024.1498459","journal-title":"Front Mol Neurosci"},{"key":"5359_CR74","doi-asserted-by":"publisher","first-page":"102640","DOI":"10.1016\/j.arr.2024.102640","volume":"91","author":"JA Wiseman","year":"2025","unstructured":"Wiseman JA, Reddy K, Dieriks BV (2025) From onset to advancement: the temporal spectrum of \u03b1-synuclein in synucleinopathies. Ageing Res Rev 91:102640. https:\/\/doi.org\/10.1016\/j.arr.2024.102640","journal-title":"Ageing Res Rev"},{"key":"5359_CR75","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1093\/brain\/awaa268","volume":"143","author":"NI Bohnen","year":"2020","unstructured":"Bohnen NI, Postuma RB (2020) Body-first versus brain-first biological subtyping of Parkinson\u2019s disease. Brain 143:2871\u20132873. https:\/\/doi.org\/10.1093\/brain\/awaa268","journal-title":"Brain"},{"key":"5359_CR76","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00702-023-02601-x","volume":"130","author":"U W\u00fcllner","year":"2023","unstructured":"W\u00fcllner U, Borghammer P, Choe CU et al (2023) The heterogeneity of Parkinson\u2019s disease. J Neural Transm 130:827\u2013838. https:\/\/doi.org\/10.1007\/s00702-023-02601-x","journal-title":"J Neural Transm"},{"key":"5359_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00730-1","author":"Z Xu","year":"2024","unstructured":"Xu Z, Hu T, Xu C et al (2024) Disease progression in proposed brain-first and body-first Parkinson\u2019s disease subtypes. NPJ Parkinsons Dis. https:\/\/doi.org\/10.1038\/s41531-024-00730-1","journal-title":"NPJ Parkinsons Dis"},{"key":"5359_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00630-7","author":"J Lee","year":"2023","unstructured":"Lee J, Sung KW, Bae EJ et al (2023) Targeted degradation of \u237a-synuclein aggregates in Parkinson\u2019s disease using the AUTOTAC technology. Mol Neurodegener. https:\/\/doi.org\/10.1186\/s13024-023-00630-7","journal-title":"Mol Neurodegener"},{"key":"5359_CR79","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179633","author":"R Han","year":"2024","unstructured":"Han R, Wang Q, Xiong X et al (2024) Deficiency of parkin causes neurodegeneration and accumulation of pathological \u03b1-synuclein in monkey models. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI179633","journal-title":"J Clin Invest"},{"key":"5359_CR80","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1074\/mcp.R113.032730","volume":"12","author":"AW Schmid","year":"2013","unstructured":"Schmid AW, Fauvet B, Moniatte M, Lashuel HA (2013) Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol Cell Proteomics 12:3543\u20133558","journal-title":"Mol Cell Proteomics"},{"key":"5359_CR81","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5483\/BMBRep.2022.55.7.073","volume":"55","author":"H Yoo","year":"2022","unstructured":"Yoo H, Lee J, Kim B et al (2022) Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson\u2019s disease. BMB Rep 55:323\u2013335. https:\/\/doi.org\/10.5483\/BMBRep.2022.55.7.073","journal-title":"BMB Rep"},{"key":"5359_CR82","doi-asserted-by":"publisher","unstructured":"Saramowicz K, Siwecka N, Galita G et al (2024) Alpha-synuclein contribution to neuronal and glial damage in Parkinson\u2019s disease. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms25010360","DOI":"10.3390\/ijms25010360"},{"key":"5359_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158338","author":"A Jan","year":"2021","unstructured":"Jan A, Gon\u00e7alves NP, Vaegter CB et al (2021) The prion-like spreading of alpha-synuclein in Parkinson\u2019s disease: update on models and hypotheses. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22158338","journal-title":"Int J Mol Sci"},{"key":"5359_CR84","doi-asserted-by":"publisher","unstructured":"Shim KH, Kang MJ, Youn YC et al (2022) Alpha-synuclein: a pathological factor with A\u03b2 and tau and biomarker in Alzheimer\u2019s disease. Alzheimers Res Ther 14. https:\/\/doi.org\/10.1186\/s13195-022-01151-2","DOI":"10.1186\/s13195-022-01151-2"},{"key":"5359_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00822-3","author":"N Franzmeier","year":"2025","unstructured":"Franzmeier N, Roemer-Cassiano SN, Bernhardt AM et al (2025) Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer\u2019s disease. Mol Neurodegener. https:\/\/doi.org\/10.1186\/s13024-025-00822-3","journal-title":"Mol Neurodegener"},{"key":"5359_CR86","doi-asserted-by":"publisher","first-page":"18276","DOI":"10.1021\/jacs.3c03212","volume":"145","author":"DM Vadukul","year":"2023","unstructured":"Vadukul DM, Papp M, Thrush RJ et al (2023) \u0391-synuclein aggregation is triggered by oligomeric amyloid-\u03b2 42 via heterogeneous primary nucleation. J Am Chem Soc 145:18276\u201318285. https:\/\/doi.org\/10.1021\/jacs.3c03212","journal-title":"J Am Chem Soc"},{"key":"5359_CR87","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12031-016-0829-1","volume":"60","author":"X Li","year":"2016","unstructured":"Li X, James S, Lei P (2016) Interactions between \u03b1-synuclein and tau protein: implications to neurodegenerative disorders. J Mol Neurosci 60:298\u2013304. https:\/\/doi.org\/10.1007\/s12031-016-0829-1","journal-title":"J Mol Neurosci"},{"key":"5359_CR88","doi-asserted-by":"publisher","unstructured":"Chen LeC, Kuo MC, Wu WC et al (2022) Advanced brain aging in multiple system atrophy compared to Parkinson\u2019s disease. NeuroImage: Clinical 34. https:\/\/doi.org\/10.1016\/j.nicl.2022.102997","DOI":"10.1016\/j.nicl.2022.102997"},{"key":"5359_CR89","doi-asserted-by":"publisher","unstructured":"Woerman AL, Watts JC, Aoyagi A et al (2018) A-synuclein: multiple system atrophy prions. Cold Spring Harb Perspect Med 8. https:\/\/doi.org\/10.1101\/cshperspect.a024588","DOI":"10.1101\/cshperspect.a024588"},{"key":"5359_CR90","doi-asserted-by":"publisher","first-page":"35050","DOI":"10.1074\/jbc.M201650200","volume":"277","author":"ZZ Pan","year":"2002","unstructured":"Pan ZZ, Bruening W, Giasson BI et al (2002) \u0393-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem 277:35050\u201335060. https:\/\/doi.org\/10.1074\/jbc.M201650200","journal-title":"J Biol Chem"},{"key":"5359_CR91","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1096\/fj.07-8379rev","volume":"21","author":"M Ahmad","year":"2007","unstructured":"Ahmad M, Attoub S, Singh MN et al (2007) \u03b3-Synuclein and the progression of cancer. FASEB J 21:3419\u20133430. https:\/\/doi.org\/10.1096\/fj.07-8379rev","journal-title":"FASEB J"},{"key":"5359_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073786","author":"I Surgucheva","year":"2013","unstructured":"Surgucheva I, Gunewardena S, Rao HS, Surguchov A (2013) Cell-specific post-transcriptional regulation of \u03b3-synuclein gene by micro-RNAs. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0073786","journal-title":"PLoS ONE"},{"key":"5359_CR93","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cellsig.2015.10.018","volume":"28","author":"V Siddartha Yerramilli","year":"2016","unstructured":"Siddartha Yerramilli V, Scarlata S (2016) The breast cancer susceptibility gene product (\u03b3-synuclein) alters cell behavior through it interaction with phospholipase C\u03b2. Cell Signal 28:91\u201399. https:\/\/doi.org\/10.1016\/j.cellsig.2015.10.018","journal-title":"Cell Signal"},{"key":"5359_CR94","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.7150\/ijbs.69155","volume":"18","author":"J Liu","year":"2022","unstructured":"Liu J, Shao T, Zhang J et al (2022) Gamma synuclein promotes cancer metastasis through the MKK3\/6-p38MAPK cascade. Int J Biol Sci 18:3167\u20133177. https:\/\/doi.org\/10.7150\/ijbs.69155","journal-title":"Int J Biol Sci"},{"key":"5359_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2023.109698","author":"HM Yang","year":"2023","unstructured":"Yang HM, Cheng YZ, Hou TZ et al (2023) Upregulation of Parkinson\u2019s disease-associated protein alpha-synuclein suppresses tumorigenesis via interaction with mGluR5 and gamma-synuclein in liver cancer. Arch Biochem Biophys. https:\/\/doi.org\/10.1016\/j.abb.2023.109698","journal-title":"Arch Biochem Biophys"},{"key":"5359_CR96","doi-asserted-by":"publisher","unstructured":"Surguchov A, Surguchev A (2022) Synucleins: new data on misfolding, aggregation and role in diseases. Biomedicines 10. https:\/\/doi.org\/10.3390\/biomedicines10112785","DOI":"10.3390\/biomedicines10112785"},{"key":"5359_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/oncm.16748","volume":"1","author":"A Surguchov","year":"2016","unstructured":"Surguchov A (2016) \u03b3-Synuclein as a cancer biomarker: viewpoint and new approaches. Oncomedicine 1:1\u20133. https:\/\/doi.org\/10.7150\/oncm.16748","journal-title":"Oncomedicine"},{"key":"5359_CR98","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1002\/ijc.33386","volume":"148","author":"S Li","year":"2021","unstructured":"Li S, Yi M, Dong B et al (2021) The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. Int J Cancer 148:2640\u20132651","journal-title":"Int J Cancer"},{"key":"5359_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110675","author":"KE Carnazza","year":"2022","unstructured":"Carnazza KE, Komer LE, Xie YX et al (2022) Synaptic vesicle binding of \u03b1-synuclein is modulated by \u03b2- and \u03b3-synucleins. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2022.110675","journal-title":"Cell Rep"},{"key":"5359_CR100","doi-asserted-by":"publisher","unstructured":"Krawczuk D, Groblewska M, Mroczko J et al (2024) The role of \u03b1-synuclein in etiology of neurodegenerative diseases. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms25030559","DOI":"10.3390\/ijms25030559"},{"key":"5359_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00570-5","volume":"9","author":"FJ Hart de Ruyter","year":"2023","unstructured":"Hart de Ruyter FJ, Morrema THJ, den Haan J et al (2023) \u03b1-Synuclein pathology in post-mortem retina and optic nerve is specific for \u03b1-synucleinopathies. NPJ Parkinsons Dis 9:124. https:\/\/doi.org\/10.1038\/s41531-023-00570-5","journal-title":"NPJ Parkinsons Dis"},{"key":"5359_CR102","doi-asserted-by":"publisher","unstructured":"Zaltieri M, Longhena F, Pizzi M et al (2015) Mitochondrial dysfunction and \u03b1 -synuclein synaptic pathology in Parkinson\u2019s disease: who\u2019s on first? Parkinsons Dis. https:\/\/doi.org\/10.1155\/2015\/108029","DOI":"10.1155\/2015\/108029"},{"key":"5359_CR103","doi-asserted-by":"publisher","unstructured":"Su R, Zhou T (2021) Alpha-synuclein induced immune cells activation and associated therapy in Parkinson\u2019s disease. Front Aging Neurosci 13. https:\/\/doi.org\/10.3389\/fnagi.2021.690748","DOI":"10.3389\/fnagi.2021.690748"},{"key":"5359_CR104","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/sclerosis2030009","volume":"2","author":"MS Patil","year":"2024","unstructured":"Patil MS, Lin LY, Marsh-Wakefield F et al (2024) Multiple sclerosis: immune cells, histopathology, and therapeutics. Sclerosis 2:117\u2013139. https:\/\/doi.org\/10.3390\/sclerosis2030009","journal-title":"Sclerosis"},{"key":"5359_CR105","doi-asserted-by":"publisher","unstructured":"Mazzotta GM, Conte C (2024) Alpha synuclein toxicity and non-motor Parkinson\u2019s. Cells 13. https:\/\/doi.org\/10.3390\/cells13040787","DOI":"10.3390\/cells13040787"},{"key":"5359_CR106","doi-asserted-by":"publisher","first-page":"276","DOI":"10.4161\/adip.25162","volume":"2","author":"S Millership","year":"2013","unstructured":"Millership S, Ninkina N, Rochford JJ, Buchman VL (2013) \u03b3-synuclein is a novel player in the control of body lipid metabolism. Adipocyte 2:276\u2013280. https:\/\/doi.org\/10.4161\/adip.25162","journal-title":"Adipocyte"},{"key":"5359_CR107","doi-asserted-by":"publisher","unstructured":"Fazio S, Bellavite P, Affuso F (2024) Chronically increased levels of circulating insulin secondary to insulin resistance: a silent killer. Biomedicines 12. https:\/\/doi.org\/10.3390\/biomedicines12081959","DOI":"10.3390\/biomedicines12081959"},{"key":"5359_CR108","doi-asserted-by":"publisher","unstructured":"Du T, Wang L, Liu W et al (2021) Biomarkers and the role of \u03b1-synuclein in Parkinson\u2019s disease. Front Aging Neurosci 13. https:\/\/doi.org\/10.3389\/fnagi.2021.740299","DOI":"10.3389\/fnagi.2021.740299"},{"key":"5359_CR109","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ane.12203","volume":"130","author":"N Malek","year":"2014","unstructured":"Malek N, Swallow D, Grosset KA et al (2014) Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson\u2019s disease - a systematic review. Acta Neurol Scand 130:59\u201372. https:\/\/doi.org\/10.1111\/ane.12203","journal-title":"Acta Neurol Scand"},{"key":"5359_CR110","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1093\/brain\/awn123","volume":"131","author":"T Pan","year":"2008","unstructured":"Pan T, Kondo S, Le W, Jankovic J (2008) The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson\u2019s disease. Brain 131:1969\u20131978. https:\/\/doi.org\/10.1093\/brain\/awn123","journal-title":"Brain"},{"key":"5359_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/cells8060565","author":"ML Arotcarena","year":"2019","unstructured":"Arotcarena ML, Teil M, Dehay B (2019) Autophagy in synucleinopathy: the overwhelmed and defective machinery. Cells. https:\/\/doi.org\/10.3390\/cells8060565","journal-title":"Cells"},{"key":"5359_CR112","doi-asserted-by":"publisher","unstructured":"Braun RJ (2015) Ubiquitin-Dependent proteolysis in yeast cells expressing neurotoxic proteins. Front Mol Neurosci 8. https:\/\/doi.org\/10.3389\/fnmol.2015.00008","DOI":"10.3389\/fnmol.2015.00008"},{"key":"5359_CR113","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/tra2.12266","volume":"7","author":"P Kumar","year":"2023","unstructured":"Kumar P, Choudhary A, Kinger S et al (2023) Proteostasis defects: medicinal challenges of imperfect aging & neurodegeneration. Transl Med Aging 7:87\u201397. https:\/\/doi.org\/10.1002\/tra2.12266","journal-title":"Transl Med Aging"},{"key":"5359_CR114","doi-asserted-by":"publisher","unstructured":"Menon S, Armstrong S, Hamzeh A et al (2022) Alpha-synuclein targeting therapeutics for Parkinson\u2019s disease and related synucleinopathies. Front Neurol 13. https:\/\/doi.org\/10.3389\/fneur.2022.876984","DOI":"10.3389\/fneur.2022.876984"},{"key":"5359_CR115","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.immuni.2024.03.010","volume":"57","author":"S Castro-Gomez","year":"2024","unstructured":"Castro-Gomez S, Heneka MT (2024) Innate immune activation in neurodegenerative diseases. Immunity 57:790\u2013814. https:\/\/doi.org\/10.1016\/j.immuni.2024.03.010","journal-title":"Immunity"},{"key":"5359_CR116","doi-asserted-by":"publisher","unstructured":"Dabi YT, Ajagbe AO, Degechisa ST (2023) Toll-like receptors in pathogenesis of neurodegenerative diseases and their therapeutic potential. Immun Inflamm Dis 11. https:\/\/doi.org\/10.1002\/iid3.850","DOI":"10.1002\/iid3.850"},{"key":"5359_CR117","doi-asserted-by":"publisher","unstructured":"Ferreira SA, Romero-Ramos M (2018) Microglia response during Parkinson\u2019s disease: alpha-synuclein intervention. Front Cell Neurosci 12. https:\/\/doi.org\/10.3389\/fncel.2018.00181","DOI":"10.3389\/fncel.2018.00181"},{"key":"5359_CR118","doi-asserted-by":"publisher","unstructured":"Gao C, Jiang J, Tan Y, Chen S (2023) Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther 8. . https:\/\/doi.org\/10.1038\/s41392-023-01444-7","DOI":"10.1038\/s41392-023-01444-7"},{"key":"5359_CR119","doi-asserted-by":"publisher","unstructured":"Muzio L, Viotti A, Martino G (2021) Microglia in neuroinflammation and neurodegeneration: from understanding to therapy. Front Neurosci 15. https:\/\/doi.org\/10.3389\/fnins.2021.698126","DOI":"10.3389\/fnins.2021.698126"},{"key":"5359_CR120","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4161\/oxim.3.4.13402","volume":"3","author":"HJ Lee","year":"2010","unstructured":"Lee HJ, Kim C, Lee SJ (2010) Alpha-synuclein stimulation of astrocytes: potential role for neuroinflammation and neuroprotection. Oxid Med Cell Longev 3:283\u2013287. https:\/\/doi.org\/10.4161\/oxim.3.4.13402","journal-title":"Oxid Med Cell Longev"},{"key":"5359_CR121","doi-asserted-by":"publisher","unstructured":"Zhao Y, Huang Y, Cao Y, Yang J (2024) Astrocyte-mediated neuroinflammation in neurological conditions. Biomolecules 14. https:\/\/doi.org\/10.3390\/biom14010037","DOI":"10.3390\/biom14010037"},{"key":"5359_CR122","doi-asserted-by":"publisher","unstructured":"Sun M, You H, Hu X et al (2023) Microglia\u2013astrocyte interaction in neural development and neural pathogenesis. Cells 12. https:\/\/doi.org\/10.3390\/cells12010033","DOI":"10.3390\/cells12010033"},{"key":"5359_CR123","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12035-012-8333-4","volume":"47","author":"L Fellner","year":"2013","unstructured":"Fellner L, Stefanova N (2013) The role of glia in \u03b1-synucleinopathies. Mol Neurobiol 47:575\u2013586. https:\/\/doi.org\/10.1007\/s12035-012-8333-4","journal-title":"Mol Neurobiol"},{"key":"5359_CR124","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddz241","author":"A Ikeda","year":"2019","unstructured":"Ikeda A, Nishioka K, Meng H et al (2019) Mutations in CHCHD2 cause \u03b1-synuclein aggregation. Hum Mol Genet. https:\/\/doi.org\/10.1093\/hmg\/ddz241","journal-title":"Hum Mol Genet"},{"key":"5359_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-45078-3","author":"D Sastre","year":"2023","unstructured":"Sastre D, Zafar F, Torres CAM et al (2023) Inactive S. aureus Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in human stem cell model of Parkinson\u2019s disease. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-023-45078-3","journal-title":"Sci Rep"},{"key":"5359_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.110449","author":"L Shen","year":"2025","unstructured":"Shen L, Zhang J, Wang Z et al (2025) Targeted degradation of \u03b1-synuclein by arginine-based PROTACs. J Biol Chem. https:\/\/doi.org\/10.1016\/j.jbc.2025.110449","journal-title":"J Biol Chem"},{"key":"5359_CR127","doi-asserted-by":"publisher","unstructured":"Sidoryk-W\u0119grzynowicz M, Adamiak K, Stru\u017cy\u0144ska L (2024) Targeting protein misfolding and aggregation as a therapeutic perspective in neurodegenerative disorders. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms25040863","DOI":"10.3390\/ijms25040863"},{"key":"5359_CR128","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00401-019-02023-x","volume":"138","author":"M Wegrzynowicz","year":"2019","unstructured":"Wegrzynowicz M, Bar-On D, Calo\u2019 L et al (2019) Depopulation of dense \u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson\u2019s disease model. Acta Neuropathol 138:575\u2013595. https:\/\/doi.org\/10.1007\/s00401-019-02023-x","journal-title":"Acta Neuropathol"},{"key":"5359_CR129","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12770-x","author":"M Alfaidi","year":"2025","unstructured":"Alfaidi M, Barker RA, Kuan WL (2025) An update on immune-based alpha-synuclein trials in Parkinson\u2019s disease. J Neurol. https:\/\/doi.org\/10.1007\/s00415-024-12770-x","journal-title":"J Neurol"},{"key":"5359_CR130","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1021\/acs.jproteome.3c00207","volume":"22","author":"W Chen","year":"2023","unstructured":"Chen W, Ding Z, Zang Y, Liu X (2023) Characterization of proteoform post-translational modifications by top-down and bottom-up mass spectrometry in conjunction with annotations. J Proteome Res 22:3178\u20133189. https:\/\/doi.org\/10.1021\/acs.jproteome.3c00207","journal-title":"J Proteome Res"},{"key":"5359_CR131","doi-asserted-by":"crossref","unstructured":"Pons M-L, Mohaupt P, Vialaret J et al (2023) Plasma \u03b1-synuclein domain profiles across \u03b1-synucleinopathies","DOI":"10.1101\/2023.07.17.23292753"},{"key":"5359_CR132","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1039\/d3an01680c","volume":"149","author":"M Cheung See Kit","year":"2023","unstructured":"Cheung See Kit M, Cropley TC, Bleiholder C et al (2023) The role of solvation on the conformational landscape of \u03b1-synuclein. Analyst 149:125\u2013136. https:\/\/doi.org\/10.1039\/d3an01680c","journal-title":"Analyst"},{"key":"5359_CR133","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/brain\/awab005","volume":"144","author":"A Stefani","year":"2021","unstructured":"Stefani A, Iranzo A, Holzknecht E et al (2021) Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain 144:1118\u20131126. https:\/\/doi.org\/10.1093\/brain\/awab005","journal-title":"Brain"},{"key":"5359_CR134","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/mds.27907","volume":"35","author":"S Manne","year":"2020","unstructured":"Manne S, Kondru N, Jin H et al (2020) \u03b1-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson\u2019s disease patients. Mov Disord 35:268\u2013278. https:\/\/doi.org\/10.1002\/mds.27907","journal-title":"Mov Disord"},{"key":"5359_CR135","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaneurol.2020.3311","volume":"78","author":"Z Wang","year":"2021","unstructured":"Wang Z, Becker K, Donadio V et al (2021) Skin \u03b1-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol 78:30\u201340. https:\/\/doi.org\/10.1001\/jamaneurol.2020.3311","journal-title":"JAMA Neurol"},{"key":"5359_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216764","author":"H Ruesink","year":"2019","unstructured":"Ruesink H, Reimer L, Gregersen E et al (2019) Stabilization of \u03b1-synuclein oligomers using formaldehyde. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0216764","journal-title":"PLoS ONE"},{"key":"5359_CR137","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00401-019-01961-w","volume":"137","author":"H Sekiya","year":"2019","unstructured":"Sekiya H, Kowa H, Koga H et al (2019) Wide distribution of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation. Acta Neuropathol 137:455\u2013466. https:\/\/doi.org\/10.1007\/s00401-019-01961-w","journal-title":"Acta Neuropathol"},{"key":"5359_CR138","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1002\/jnr.24927","volume":"99","author":"A Behere","year":"2021","unstructured":"Behere A, Th\u00f6rnqvist PO, Winberg S et al (2021) Visualization of early oligomeric \u03b1-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]\u03b1-syn transgenic mouse model. J Neurosci Res 99:2525\u20132539. https:\/\/doi.org\/10.1002\/jnr.24927","journal-title":"J Neurosci Res"},{"key":"5359_CR139","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaf011","author":"A Dhakal","year":"2024","unstructured":"Dhakal A, Gyawali R, Wang L, Cheng J (2024) Artificial intelligence in cryo-EM protein particle picking: recent advances and remaining challenges. Brief Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbaf011","journal-title":"Brief Bioinform"},{"key":"5359_CR140","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1084\/jem.20112457","volume":"209","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm VM, Zhang B et al (2012) Intracerebral inoculation of pathological \u03b1-synuclein initiates a rapidly progressive neurodegenerative \u03b1-synucleinopathy in mice. J Exp Med 209:975\u2013988. https:\/\/doi.org\/10.1084\/jem.20112457","journal-title":"J Exp Med"},{"key":"5359_CR141","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s13311-022-01288-7","volume":"19","author":"L Knecht","year":"2022","unstructured":"Knecht L, Folke J, Dodel R et al (2022) Alpha-synuclein immunization strategies for synucleinopathies in clinical studies: a biological perspective. Neurotherapeutics 19:1489\u20131502. https:\/\/doi.org\/10.1007\/s13311-022-01288-7","journal-title":"Neurotherapeutics"},{"key":"5359_CR142","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-024-02706-0","author":"J Rutledge","year":"2024","unstructured":"Rutledge J, Lehallier B, Zarifkar P et al (2024) Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson\u2019s disease. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-024-02706-0","journal-title":"Acta Neuropathol"},{"key":"5359_CR143","doi-asserted-by":"publisher","first-page":"6439","DOI":"10.1021\/acs.jpcb.4c00342","volume":"128","author":"F Bergasa-Caceres","year":"2024","unstructured":"Bergasa-Caceres F, Rabitz HA (2024) A perspective on interdicting in protein misfolding for therapeutic drug design: modulating the formation of nonlocal contacts in \u03b1-synuclein as a strategy against Parkinson\u2019s disease. J Phys Chem B 128:6439\u20136448. https:\/\/doi.org\/10.1021\/acs.jpcb.4c00342","journal-title":"J Phys Chem B"},{"key":"5359_CR144","doi-asserted-by":"publisher","unstructured":"Azevedo R, Jacquemin C, Villain N et al (2022) Mass spectrometry for neurobiomarker discovery: the relevance of post-translational modifications. Cells 11. https:\/\/doi.org\/10.3390\/cells11162532","DOI":"10.3390\/cells11162532"},{"key":"5359_CR145","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2147\/NDT.S165777","volume":"14","author":"T Carnwath","year":"2018","unstructured":"Carnwath T, Mohammed R, Tsiang D (2018) The direct and indirect effects of \u03b1-synuclein on microtubule stability in the pathogenesis of Parkinson\u2019s disease. Neuropsychiatr Dis Treat 14:1685\u20131695. https:\/\/doi.org\/10.2147\/NDT.S165777","journal-title":"Neuropsychiatr Dis Treat"},{"key":"5359_CR146","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1021\/acs.jproteome.3c00266","volume":"22","author":"A Po","year":"2023","unstructured":"Po A, Eyers CE (2023) Top-down proteomics and the challenges of true proteoform characterization. J Pteome Res 22:3663\u20133675. https:\/\/doi.org\/10.1021\/acs.jproteome.3c00266","journal-title":"J Pteome Res"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05359-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05359-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05359-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T08:03:07Z","timestamp":1763539387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05359-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":146,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5359"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05359-6","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"87"}}